Discover and read the best of Twitter Threads about #Apixabán

Most recents (11)

1/

Second day of @Smart_Meeting_M

Professor @giovannilandoni talking about management of #anticoagulant in #perioperative patients 💉

✅You surely all know how to deal with #antithrombotic and #regionalanesthesia, here the guidelines:

pubmed.ncbi.nlm.nih.gov/34980845/

#FOAMed #FOAMcc Image
2/

💡Let's focus on perioperative #DOAC /#NOAC / #TSOAC

➡️Consider both #surgical blood loss risk and #patient characteristics.

⚠️Remember NOT to bridge with #LMWH or #UFH.

pubmed.ncbi.nlm.nih.gov/33895845/ Image
3/

What if it's not an elective patient??

Use #reversal agents when needed❗

🔹#Idarucizumab for #dabigatran
🔹#Andexanet for #apixaban and #rivaroxaban
💡#Prothrombin complex concentrates in addiction

pubmed.ncbi.nlm.nih.gov/36988142/ Image
Read 7 tweets
1a) Welcome to a new #accredited #tweetorial on the management of aFXa-DOAC-associated #hemorrhage and specifically the role of coag laboratory testing in these challenging cases.
1b) Our expert author is #pharmacist Craig Beavers, PharmD @beaverspharmd CV Clinical Pharmacy Specialist @UK_COP, and Immediate Past Chair of the @ACCinTouch #ACCCVT Section
2) This 🆓program is accredited for 0.5h CE/#CME for #physicians #physicianassociates #nurses #nurespractitioners #pharmacists and is supported by a grant from AstraZeneca. See statement of accreditation and faculty disclosures at cardiometabolic-ce.com/disclosures/.
Read 37 tweets
1a) Welcome to a new #accredited #tweetorial on a very challenging topic: managing #ICH in a patient taking anti-FXa #DOACs! Your expert authors are both #neurointensivists: Richard Choi, DO @rkchoi @christianacare and Casey Albin, MD @caseyalbin @EmoryNeuroCrit ImageImage
1b) #Physicians #Nurses #Pharmacists #physicianassociate #NPs earn 0.5h CE/#CME from @academiccme for following this 🧵 Image
2) This program is supported by an educational grant from AstraZeneca and is intended for #HCPs. Accreditation statement and faculty disclosures at cardiometabolic-ce.com/disclosures/. Prior (& future) programs in this space, available for 🆓CE/#CME credit, at cardiometabolic-ce.com/category/antit….
Read 52 tweets
1) Welcome to an #accredited #tweetorial on a unique emerging (in Ph3 now) option for specifically reversing the #antiplatelet effects of #ticagrelor: it's #bentracimab. Expert faculty is antithrombotic agent reversal guru @md_pollack of @UMMCnews, working to create #AHealthierMS
2) This program is intended for #healthcare professionals and is supported by an educational grant from PhaseBio Pharmaceuticals. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/, and prior programs are available for 🆓CE/#CME credit at cardiometabolic-ce.com.
3) It is an unfortunate fact of life that one cannot prescribe #anticoagulant or #antiplatelet (together, #antithrombotic) therapy without increasing a patient's #bleedingrisk. That is why it should be an individualized risk:benefit decision, ideally . . .
Read 51 tweets
1) Welcome to a new #accredited #tweetorial on managing #VTE at the extremes of weight & renal function. Free CE/#CME credit for following along with expert author @AryaRoopen from King’s Thrombosis Centre at King's College Hospital in London! Only the best for our learners! Image
2) When we think about "special populations" in #VTE, we think weight, age, and #cancer status. @aakonc already addressed the last of those (earn credit still at cardiometabolic-ce.com/antithrombotic…). Learn the rest here! Hello to @ProfMakris @bhwords @MiddeldorpS @fniainle @AliTaherMD
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures at cardiometabolic-ce.com/disclosures/. Credit for #physicians #physicianassociates #nurses #NPs #pharmacists
Read 51 tweets
1) Welcome to a new #accredited #tweetorial on a🗝️ topic in #cancer care & #vascular medicine: #VTE (#DVT and #PE). Cancer patients are at⬆️risk from their disease, their comorbidities, & often from their treatment. It's a sticky wicket & @cardiomet_CE is proud to welcome ...
2) ... one of the world's leading authorities on cancer-associated VTE as new faculty both here and on @onc_ce: Dr. Alok Khorana @aakonc of @ClevelandClinic, to talk about advances and best treatment in this space!
3) This educational program is intended for health care providers & is supported by a grant from Bristol Myers Squibb & its Alliance partner Pfizer, Inc. Faculty disclosures are listed at cardiometabolic-ce.com/disclosures/. Earn CE/#CME credit from prior programs at cardiometabolic-ce.com.
Read 39 tweets
In our @JAMA_current editorial, we tackle a timely question in #CardioTwitter: should we recommend #apixaban or #rivaroxaban as first-line anticoagulant for #Afib?The two #DOACs are not interchangeable for bleeding or stroke. Let's review all RCTs & RWE🧵
jamanetwork.com/journals/jama/… Image
Why should you care? Why now? 1) >70% of #Medicare pts on anticoagulation are taking #DOACs, practically replacing warfarin 2) Generic DOACs will enter the market in 2022, massively ⬆️ patient access & use 3) Insurance companies may not cover all DOACs in their formularies 💵💊 Image
RCTs first: in ROCKET-AF (n=14K pts), riva was NON-INFERIOR to warfarin for stroke (per-protocol)🧠, w/ similar rates of major/non-major bleed🩸. In ARISTOTLE (n=18K pts), apixa was SUPERIOR to warfarin for stroke (ITT)🧠 AND w significantly⬇️ major bleed🩸, AND even⬇️mortality. Image
Read 17 tweets
Don’t miss a new accredited #tweetorial launching TOMORROW here on @cardiomet_CE. #Emergencymedicine #thrombosis researcher @md_pollack will be discussing safe, effective management of selected patients with venous thromboembolism (#VTE) from the #emergencydepartment.
It used to be SOOO much more complicated, but since we entered the era of the #DOACs, #lifeisgood! #Physicians #nurses #pharamcists all work together to make it happen, and all can earn CE/#CME here! @AlexSpyropoul @ScottKaatz @RenatoDLopes1 @GenoMerli @aakonc @vic_tapson
1) Welcome to a #tweetorial on the safe and effective management of acute venous #thromboembolism (#VTE) directly from the #emergencydepartment. This program is accredited for 0.50 credits for #physicians #nurses #pharmacists by @academiccme! I am @md_pollack. Image
Read 23 tweets
#ACC21 late-breakers🧵
1/Antiplatelets: Let's start with #aspirin
❌ADAPTABLE :Aspirin 325 mg vs 81 mg in ASCVD pts
No difference in death/ MI/ stroke/major bleeding
💎pragmatic trial: EHR-identified pts
💎significant dose switching in 325 mg group
nejm.org/doi/full/10.10…
✅Host Exam: Aspirin vs Clopidogrel in chronic Maintenance monotherapy after #PCI w/ DES
#Clopidogrel monotherapy reduced composite of death, non-fatal MI, stroke, ACS re-admission, BARC >=3 bleeding, compared to #aspirin monotherapy.
❓East Asian paradox
thelancet.com/journals/lance…
✅TALOS- AMI: De-escalation ✅
In pts w/ no major events in 1st month after index PCI, de-escalation of DAPT from #ticagrelor to #clopidogrel is superior to tica-only DAPT in terms of net clinical benefit, with
⬇️decreased bleeding 🩸risk
- no increase in ischaemic risk
#ACC21
Read 16 tweets
#FibrilaciónAuricular
#Anticoagulación

🧐Revisiones muy útiles siempre para afianzar conceptos.
👏Si además son compañeros🇪🇸 me quito el 🎩
👩‍🎓En tres minutos se repasa la FA y su tratamiento
💊ACOD hay que saberse todo! #MIR #MIR2021 #EIR
🧓Pensar en los mayores siempre! Image
1⃣ACOD
2⃣Riesgo embólico vs Hemorrágico
3⃣Edad
4⃣Problemas de dosis (Cuidado!🆘)

The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation | Journal of Comparative Effectiveness Research futuremedicine.com/doi/full/10.22… Image
1⃣La #FA es un problema muy común🌏
2⃣Crecimiento en los próximos años
3⃣Aumento de prevalencia con la edad🧓
4⃣Aumento de complicaciones con la edad🧓 Image
Read 13 tweets
#WeeklyCardioReview AUGUSTUS trial #NeverTooLate #Apixaban in patients requiring DAPT. Two key aspects to discuss here: 1) Should Apixaban 5mg/BID be the only NOAC used with triple therapy? 2) Time to move to NOAC+Clopidogrel dual therapy? enjoy thread and comment! 😉
Summary: AUGUSTUS RCT 4,614 ppl requiring DAPT (ACS and-or PCI) factorial design: Apixa vs Warfarin (NOAC research question), and ASA vs placebo (triple vs dual tx question) for 6 months. Study powered for bleeding outcomes and had guts to assume no interaction, stay tuned
Major or clinically relevant nonmajor bleeding lower in Apixa vs Warfarin HR 0.69 (0.58-0.81; superiority P<0.001), ASA vs placebo 1.89 (1.59-2.24; placebo superiority P<0.001). Apixa Vs Warfa, and ASA vs placebo similar incidence of ischemic events
Read 21 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!